Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Oct;24(4):538–543. doi: 10.1128/aac.24.4.538

Comparison of the efficacy of vidarabine, its carbocyclic analog (cyclaradine), and cyclaradine-5'-methoxyacetate in the treatment of herpes simplex virus type 1 encephalitis in mice.

W M Shannon, L Westbrook, G Arnett, S Daluge, H Lee, R Vince
PMCID: PMC185370  PMID: 6651280

Abstract

The relative therapeutic effects of vidarabine (9-beta-D-arabinofuranosyladenine), cyclaradine (the adenosine deaminase-resistant carbocyclic analog of vidarabine), and cyclaradine-5'-methoxyacetate in the parenteral treatment of systemic herpes simplex virus type 1 infections in Swiss mice were determined. Among control mice inoculated intraperitoneally with virus, a mortality rate of 95% was observed. The intraperitoneal administration of nontoxic doses of vidarabine (125 to 250 mg/kg per day) or cyclaradine (113 to 450 mg/kg per day), by daily injections for 7 days beginning 4 h after virus inoculation, reduced mortality to 0 to 10%. Among control animals inoculated intracerebrally with 32 50% lethal doses of virus, 100% mortality was observed, with a mean survival time of 4.6 days. Treatment with either drug at equimolar dose levels ranging from ca. 32 to 750 mg/kg per day produced significant (P less than 0.0005), dose-dependent increases in the mean survival time of animals dying of herpesvirus encephalitis. Mice inoculated intracerebrally with 10 50% lethal doses of virus exhibited 97% mortality and a mean survival time of 5.5 to 6.4 days. Treatment with vidarabine, cyclaradine, or cyclaradine-5'-methoxyacetate significantly increased the mean survival time of dying animals and, at doses ranging from 250 to 750 mg/kg per day, produced significant increases in survival. The three drugs displayed equivalent antiviral efficacy in vivo. Drug toxicity (measured by weight loss) was not detected in mice treated with cyclaradine or cyclaradine-5'-methoxyacetate at 750 mg/kg per day, whereas severe toxicity (weight loss of greater than or equal to 3 g) was observed in mice treated with vidarabine at an equivalent dose level. Thus, cyclaradine or its 5'-methoxyacetic acid ester may possess some advantage over vidarabine in the treatment of severe herpesvirus infections and should therefore be considered for clinical trials in humans.

Full text

PDF
538

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett L. L., Jr, Shannon W. M., Allan P. W., Arnett G. Studies on the biochemical basis for the antiviral activities of some nucleoside analogs. Ann N Y Acad Sci. 1975 Aug 8;255:342–358. doi: 10.1111/j.1749-6632.1975.tb29242.x. [DOI] [PubMed] [Google Scholar]
  2. Bloch A., Robins M. J., McCarthy J. R., Jr The role of the 5'-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase. J Med Chem. 1967 Sep;10(5):908–912. doi: 10.1021/jm00317a034. [DOI] [PubMed] [Google Scholar]
  3. Bryson Y., Connor J. D., Sweetman L., Carey S., Stuckey M. A., Buchanan R. Determination of plaque inhibitory activity of adenine arabinoside (9-beta-D-arabinofuranosyladenine) for herpesviruses using an adenosine deaminase inhibitor. Antimicrob Agents Chemother. 1974 Jul;6(1):98–101. doi: 10.1128/aac.6.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen S. S. Introduction to the biochemistry of D-arabinosyl nucleosides. Prog Nucleic Acid Res Mol Biol. 1966;5:1–88. doi: 10.1016/s0079-6603(08)60231-7. [DOI] [PubMed] [Google Scholar]
  5. Frederiksen S. Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine analogues. Arch Biochem Biophys. 1966 Feb;113(2):383–388. doi: 10.1016/0003-9861(66)90202-5. [DOI] [PubMed] [Google Scholar]
  6. Galasso G. J. An assessment of antiviral drugs for the management of infectious diseases in humans. Antiviral Res. 1981 Jun;1(2):73–96. doi: 10.1016/0166-3542(81)90035-8. [DOI] [PubMed] [Google Scholar]
  7. Griffith J. F., Fitzwilliam J. F., Casagrande S., Butler S. R. Experimental herpes simplex virus encephalitis: Comparative effects of treatment with cytosine arabinoside and adenine arabinoside. J Infect Dis. 1975 Nov;132(5):506–510. doi: 10.1093/infdis/132.5.506. [DOI] [PubMed] [Google Scholar]
  8. Kern E. R., Richards J. T., Overall J. C., Jr, Glasgow L. A. Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid. Antimicrob Agents Chemother. 1978 Jan;13(1):53–60. doi: 10.1128/aac.13.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. North T. W., Cohen S. S. Aranucleosides and aranucleotides in viral chemotherapy. Pharmacol Ther. 1979;4(1):81–108. doi: 10.1016/0163-7258(79)90016-0. [DOI] [PubMed] [Google Scholar]
  10. North T. W., Cohen S. S. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. Proc Natl Acad Sci U S A. 1978 Oct;75(10):4684–4688. doi: 10.1073/pnas.75.10.4684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schabel F. M., Jr The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A). Chemotherapy. 1968;13(6):321–338. doi: 10.1159/000220567. [DOI] [PubMed] [Google Scholar]
  12. Schaeffer H. J., Schwender C. F. Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem. 1974 Jan;17(1):6–8. doi: 10.1021/jm00247a002. [DOI] [PubMed] [Google Scholar]
  13. Shannon W. M., Arnett G., Schabel F. M., Jr, North T. W., Cohen S. S. Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. Antimicrob Agents Chemother. 1980 Oct;18(4):598–603. doi: 10.1128/aac.18.4.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shannon W. M., Arnett G., Westbrook L., Shealy Y. F., O'Dell C. A., Brockman R. W. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob Agents Chemother. 1981 Dec;20(6):769–776. doi: 10.1128/aac.20.6.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shannon W. M., Schabel F. M., Jr Antiviral agents as adjuncts in cancer chemotherapy. Pharmacol Ther. 1980;11(2):263–390. doi: 10.1016/0163-7258(80)90034-0. [DOI] [PubMed] [Google Scholar]
  16. Shannon W. M. Selective inhibition of RNA tumor virus replication in vitro and evaluation of candidate antiviral agents in vivo. Ann N Y Acad Sci. 1977 Mar 4;284:472–507. doi: 10.1111/j.1749-6632.1977.tb21983.x. [DOI] [PubMed] [Google Scholar]
  17. Shannon W. M., Westbrook L., Schabel F. M., Jr Antiviral activity of 9-beta-D-arabinofuranosyladenine (ara-A) against Gross murine leukemia virus in vitro. Proc Soc Exp Biol Med. 1974 Feb;145(2):542–545. doi: 10.3181/00379727-145-37848. [DOI] [PubMed] [Google Scholar]
  18. Shealy Y. F., O'Dell C. A., Shannon W. M., Arnett G. Carbocyclic analogues of 5-substituted uracil nucleosides: synthesis and antiviral activity. J Med Chem. 1983 Feb;26(2):156–161. doi: 10.1021/jm00356a008. [DOI] [PubMed] [Google Scholar]
  19. Sloan B. J., Kielty J. K., Miller F. A. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication. Ann N Y Acad Sci. 1977 Mar 4;284:60–80. doi: 10.1111/j.1749-6632.1977.tb21937.x. [DOI] [PubMed] [Google Scholar]
  20. Sloan B. J., Miller F. A., McLean I. W., Jr Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine. Antimicrob Agents Chemother. 1973 Jan;3(1):74–80. doi: 10.1128/aac.3.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Vince R., Daluge S. Carbocyclic arabinosyladenine, an adenosine deaminase resistant antiviral agent. J Med Chem. 1977 Apr;20(4):612–613. doi: 10.1021/jm00214a040. [DOI] [PubMed] [Google Scholar]
  22. Whitley R. J., Nahmias A. J., Soong S. J., Galasso G. G., Fleming C. L., Alford C. A. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980 Oct;66(4):495–501. [PubMed] [Google Scholar]
  23. Whitley R. J., Soong S. J., Dolin R., Galasso G. J., Ch'ien L. T., Alford C. A. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977 Aug 11;297(6):289–294. doi: 10.1056/NEJM197708112970601. [DOI] [PubMed] [Google Scholar]
  24. Whitley R. J., Soong S. J., Hirsch M. S., Karchmer A. W., Dolin R., Galasso G., Dunnick J. K., Alford C. A. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med. 1981 Feb 5;304(6):313–318. doi: 10.1056/NEJM198102053040602. [DOI] [PubMed] [Google Scholar]
  25. Whitley R. J., Tucker B. C., Kinkel A. W., Barton N. H., Pass R. F., Whelchel J. D., Cobbs C. G., Diethelm A. G., Buchanan R. A. Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans. Antimicrob Agents Chemother. 1980 Nov;18(5):709–715. doi: 10.1128/aac.18.5.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Whitley R. Diagnosis and treatment of herpes simplex encephalitis. Annu Rev Med. 1981;32:335–340. doi: 10.1146/annurev.me.32.020181.002003. [DOI] [PubMed] [Google Scholar]
  27. York J. L., LePage G. A. A proposed mechanism for the action of 9-beta-D-arabinofuranosyladenine as an inhibitor of the growth of some ascites cells. Can J Biochem. 1966 Jan;44(1):19–26. doi: 10.1139/o66-003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES